Byondis

Our goal is to efficiently advance our proprietary pipeline of novel ADCs & mAbs and further our earlier stage pipeline of novel immune-stimulating and cytotoxic payload linker-drug platforms and tumor-specific masking/de-masking technology. 👉 Learn more about how collaboration plays a role in Byondis’ maximizing the potential of its science, pipeline and technology: https://bit.ly/4jgAuCL #OncologyResearch

Our Founder and CEO, Jacques Lemmens, discussed key opportunities and challenges in the field of ADC development with leaders from Tubulis, Heidelberg Pharma and Adcendo at the Van Lanschot Kempen Life Sciences Conference. Highlights on how we are pushing the boundaries in the space: ➡️ Diversity of Payloads: Byondis emphasizes the need for novel payloads to overcome resistances. This diversity is crucial to address the medical need for enhancing the effectiveness of existing ADC therapies. Byondis is actively developing proprietary payloads to provide more options to ensure robust therapeutic outcomes. ➡️ Masking Techniques: Byondis is leveraging its differentiated masking technique to enhance the safety and efficacy of ADCs by reducing off-tumor toxicity to improve therapeutic outcomes. ➡️ Expanding Beyond Oncology: Investigating the potential use of ADCs in autoimmune diseases, where tolerability and therapeutic needs outside oncology might drive the next wave of ADC innovation.   Let's connect to discuss how we can collaborate and drive innovation in the ADC space together: https://bit.ly/4jgAuCL 🌟 #vlk2025

Hear from our Founder and CEO, Jacques Lemmens, PhD, about our strategic goals and milestones and how our fully-integrated discovery, development and manufacturing capabilities; in-house created pipeline of novel ADCs and mAbs and our drug development expertise will propel our progress on behalf of patients. 

Today we announced the appointment of Christoph Korpus, PhD, MBA, as Byondis' Chief Business Officer. Christoph will play a pivotal role in advancing our pipeline of novel antibody conjugates and monoclonal antibody-based therapeutics through clinical development and lead Byondis' business development efforts. Welcome Christoph! https://bit.ly/4jf4tuX

Our CEO, Jacques Lemmens, PhD, will be joining other leaders on a panel to discuss “ADCs Done Different” at the Van Lanschot Kempen Life Science Conference on April 2. Learn more: https://bit.ly/4bGeJtz

BYON4228 is a potentially best-in-class SIRPα myeloid immune checkpoint inhibitor that targets and blocks the CD47-SIRPα axis, responsible for tumors’ ability to escape from recognition and destruction by the immune system. CD47 is highly expressed on a wide range of tumor types. 

We are hiring! Learn more about our open positions in Research, Quality and Downstream Processing and how joining the Byondis team means being part of bringing a new generation of ADCs and mAbs to patients with cancer. https://bit.ly/4isYySC

Senior Director of Downstream Processing, Michel Eppink, will be speaking at the Bioprocessing Summit in Barcelona March 18-20 on Efficient Process Development of Site-Specific Antibody-Drug Conjugates.

Byondis’ Senior Director of Downstream Processing and Professor at the Dept. of Biotechnology of TU Delft, Michel Eppink, will be presenting his inaugural lecture titled "Affordable Medicines: Innovations in Bioprocessing" on February 21st at TU Delft. More information here: https://bit.ly/4b36NlQ Congratulations Michel!

Today on the International Day of Women and Girls in Science, we recognize the impact of supporting the next leaders in science and technology. We sponsor a broad array of initiatives to encourage students throughout their academic careers to pursue their interest in science, including drug research.  #11February, #WomeninScience; #GirlsinScience